0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Allergy Thera. Share Price Today
11.75
Change
1.00 (0.00%)
Bid
11.50
Ask
12.00

Spread
0.50 (4.348%)
Close
11.75
Open
11.75
High
11.75
11.75
Low
Current Price
11.75
Last Updated: 08:15:03

More about Allergy Thera.

Allergy Therapeutics Plc Ord 0.1P is listed on the London Stock Exchange trading with ticker code AGY.L, and is part of the Medicine and Biotech Research sector. It has a market capitalisation of £7,475m, with approximately 636m shares in issue. Over the last year, Allergy Thera. share price has been traded in a range of 10.4, hitting a high of 17.75, and a low of 7.35.

Allergy Therapeutics Plc, officially known as Allergy Therapeutics Plc Ord 0.1P was formed in June of 2004, making the company fifteen years old. The company filed its latest accounts on 30th June 2014, showing a turnover of approximately 41.96 million GBX with gross profits of 30.00 million, or 0.0472 per issued share, and a pre-tax profit margin of 2.58%. Allergy Therapeutics Plc currently has 6 directors, and has had 8 previous directors over the last 15 years. In the last set of accounts produced by Grant Thornton Uk Llp, the company showed 18.44 million paid in salaries to the 347 staff (average wage of 53 thousand), with the directors receiving an average 141 thousand each. In the accounts filed in 2014, the company paid 0 in dividends. These accounts also showed Allergy Therapeutics Plc to have a net worth of 11.30 million, with 2.03 million held in cash.


Allergy Thera. is in the Medicine and Biotech Research sector.

Allergy Thera. is in the AIM 100, AIM 350 indices.

What if I invested £1,000 in Allergy Thera.?
1 month ago 1 year ago
AGY.L£382.11 £489.58

Allergy Thera. Share Information

Volume 0.00
Currency GBX
Shares in Issue 636m
Market Capitalisation £7,475m
52 Week High 17.75
52 Week Low 7.35

Compare Allergy Thera.

Compare Allergy Thera. with:
Nobody has posted any Allergy Thera. share chat yet, click here to add one.
Nobody has posted any Allergy Thera. insights yet, click here to add one.